Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)

Inclusion Criteria

• •Group A Renal Cell Carcinoma:
• •Patients will be eligible for inclusion in this study if ALL of the following criteria apply:
• •1. Histologically confirmed or radiological diagnosis of renal cell carcinoma. Clear cell and non-clear cell carcinoma (such as papillary, chromophobe, collecting duct, and medullary) allowed.
• •2. Evidence of locally advanced, high grade or metastatic disease in any site on most recent imaging scan
• •3. Planned initiation of treatment with any of the following:
• •* Immune modulatory agent targeting any of the following: PD-1, PD-L1, CTLA-4, CD27, OX40, LAG3 or tumor infiltrating lymphocytes (TIL)
• •* Immune modulatory agent consisting of any of the following: CAR-T, bispecific antibody or vaccine trial.
• •4. Age \> 18 years.
• •5. Ability to understand and the willingness to sign a written informed consent document.
• •Group B Urothelial Carcinoma:
• •Patients will be eligible for inclusion in this study if ALL of the following criteria apply:
• •1. Histologically confirmed diagnosis of urothelial carcinoma. Non-transitional cell carcinoma (such as adenocarcinoma and squamous cell carcinoma) allowed.
• •2. Evidence of locally advanced, high grade or metastatic disease in any site on most recent imaging scan
• •3. Planned initiation of treatment with any of the following:
• •* Immune modulatory agent targeting any of the following: PD-1, PD-L1, CTLA-4, CD27, OX40, LAG3 or tumor infiltrating lymphocytes (TIL)
• •* Immune modulatory agent consisting of any of the following: CAR-T, bispecific antibody or vaccine trial.
• •4. Age \> 18 years.
• •5. Ability to understand and the willingness to sign a written informed consent document.